The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Plasma growth hormone as a prognostic biomarker to durvalumab and tremelimumab in patients with advanced hepatocellular carcinoma.
 
Shadi Chamseddine
No Relationships to Disclose
 
Michael Brian LaPelusa
No Relationships to Disclose
 
Lianchun Xiao
No Relationships to Disclose
 
Yehia I. Abugabal
No Relationships to Disclose
 
Sunyoung S. Lee
No Relationships to Disclose
 
Zishuo Ian Hu
No Relationships to Disclose
 
Rikita Hatia
No Relationships to Disclose
 
Manal Hassan
No Relationships to Disclose
 
James C. Yao
Consulting or Advisory Role - Acrotech Biopharma; Amgen; Crinetics Pharmaceuticals; Exelixis; Hutchison MediPharma; Ipsen
Research Funding - Advanced Accelerator Applications; Novartis
 
Dan G. Duda
No Relationships to Disclose
 
Saumil Datar
No Relationships to Disclose
 
Hesham M. Amin
No Relationships to Disclose
 
Ahmed Omar Kaseb
Honoraria - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck